Rituximab dosing and monitoring strategies in neuromyelitis optica patients: Creating strategies for therapeutic success

Multiple Sclerosis Journal

Volumn 18, Issue 7, 2012, Pages 1022-1026

  Greenberg, Benjamin M ^a   Graves, Donna ^a   Remington, Gina ^a   Hardeman, Paula ^a   Mann, Martha ^a   Karandikar, Nitin ^a   Stuve, Olaf ^a   Monson, Nancy ^a   Frohman, Elliot ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

CD19; CD20; Devic's disease; dosing; neuromyelitis optica; rituximab

Indexed keywords

CD19 ANTIGEN; RITUXIMAB;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; MALE; MANTEL COX LOG RANK TEST; MYELOOPTIC NEUROPATHY; PATIENT MONITORING; RANK SUM TEST; RELAPSE; STATISTICAL ANALYSIS; SURVIVAL;

EID: 84863195831     PISSN: 13524585     EISSN: 14770970     Source Type: Journal    
DOI: 10.1177/1352458511432896     Document Type: Article

References (10)

1. Lennon VA, Wingerchuk DM, Kryzer TJ, et al. A serum autoantibody marker of neuromyelitis optica: distinction from multiple sclerosis. Lancet 2004; 364: 2106-2112. (Pubitemid 39626806)
2. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
3. Jacob A, Matiello M, Weinshenker BG, et al. Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients. Arch Neurol 2009; 66: 1128-1133.
4. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
5. Pescovitz MD. Rituximab, an anti-cd20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006; 6: 859-866. (Pubitemid 44356635)
6. Bar-Or A, Calabresi PA, Arnold D, et al. Rituximab in relapsing-remitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400. (Pubitemid 351499869)
7. Bourdette D and Yadav V. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. Curr Neurol Neurosci Rep 2008; 8: 417-418.
8. Cree BA, Lamb S, Morgan K, Chen A, Waubant E and Genain C. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
9. Bonnan M, Brasme H, Diaby MM, Vlaicu M, Le Guern V and Zuber M. [Severe bouts of neuromyelitis optica: dramatic improvement after plasma exchanges]. Rev Neurol (Paris) 2009; 165: 479-481.
10. Fardet L, Genereau T, Mikaeloff Y, Fontaine B, Seilhean D and Cabane J. Devic's neuromyelitis optica: study of nine cases. Acta Neurol Scand 2003; 108: 193-200. (Pubitemid 37011649)